

# BIOPHARMA

## CREDIT PLC

### INVESTMENT OBJECTIVES AND STRATEGY

- 1 BioPharma Credit's objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.
- 2 The Company primarily invests in corporate and royalty debt secured by cash flows derived from sales of approved life sciences products.
- 3 Pharmakon Advisors, the Investment Manager, seeks to build a diversified portfolio with downside protection, high visibility and stability of cash flows.
- 4 Once substantially invested, BioPharma Credit will target an initial dividend yield of 7% and net total return on NAV of 8% to 9% per annum in the medium term.

### Upcoming Events

Half yearly results announced 21 September 2017

Annual results announced April 2018

### INVESTMENT TEAM



Pedro Gonzalez de Cosio  
Investment Manager



Martin Friedman  
Investment Manager



Pablo Legorreta  
Investment Manager

### TRUST FACTS

As at 31 August 2017

Ordinary shares		Assets	
Share price	\$1.12	Market capitalisation	\$849.5m
NAV per share	99.68 cents	Net assets	\$759.4m
Premium to NAV	11.86%	Fees	
Shares in issue	761.9m	Management fee	1% of NAV per annum
		Performance fee	10% <sup>1</sup>

### HIGHLIGHTS FOR THE QUARTER


- On 27 July 2017, BioPharma Credit PLC (the "Company") received a scheduled payment of \$11.1 million from RPS BioPharma Investments, LP on the RPS Note, a senior secured loan backed by royalties on 21 products, of which \$6.1 million represented repayment of principal. As of 31 August 2017, the outstanding balance on the RPS Note was \$130.8 million (excluding accrued interest) and the Company continues to believe the RPS Note will be fully repaid by the end of 2018.
- On 31 July 2017, Vivus paid 53.3% of its outstanding balance on its loan with BioPharma III. BioPharma Credit holds 46% of the Vivus capped royalty through its limited partnership interest in BioPharma III.
- On 1 August 2017, the Company received \$12.6 million from BioPharma III in the form of a scheduled distribution to its limited partners.
- On 7 August 2017, Depomed reiterated its intention to refinance its senior secured loan by 30 September. The Company's remaining balance on the Depomed loan was \$46.0 million as at 31 August 2017.
- Below is a summary of the Company's opening and closing portfolio balances for the period, excluding accrued interest on the RPS Note.

Cash (\$m)	BioPharma III (\$m)	RPS Note (\$m)
498.1	130.0	130.8
487.2	141.3	130.8
■ 31/8/2017	■ 31/7/2017	

### PERFORMANCE

#### Cumulative Performance

	1 month	2 months	3 months	Since launch
Share price	2.11%	2.11%	2.11%	11.50%
NAV per share <sup>2</sup>	0.34%	0.76%	1.03%	1.71%



1. The performance fee is calculated as 10% of outperformance above 0% return, subject to a 6% preferred return hurdle with 50% catch up.
2. As set out in the Prospectus, the Initial Expenses to be borne by the Company were capped at 2% of the Gross Issue Proceeds. The cumulative NAV performance since launch reflects the Company's performance against the expected opening NAV per share of 98 cents on the date of IPO.

# BIOPHARMA

— CREDIT PLC —

## SHAREHOLDER INFORMATION

### Trust Details

Launch Date	27 March 2017
Year end	31 December
Interim	30 June
Listing	London Stock Exchange, Channel Islands Securities Exchange

### Corporate Contacts

Registered Office	Beaufort House 51 New North Road, Exeter, EX4 4EP
Registrar	Capita Asset Services
Lawyer	Herbert Smith Freehills LLP
Auditor	PricewaterhouseCoopers LLP
Company Secretary	Capita Company Secretarial Services Limited

### Board of Directors

Jeremy Sillem (Chairman)
Colin Bond
Duncan Budge
Harry Hyman

ISIN	GB00BDGKMY29
SEDOL	BDGKMY2
Bloomberg	BPCR LN

## FOR PROFESSIONAL CLIENT USE ONLY

**THIS FACTSHEET IS NOT INTENDED TO OFFER OR TO PROMOTE THE OFFER OR TRANSFER OF THE SHARES (THE "SHARES") OF BIOPHARMA CREDIT PLC (THE "COMPANY") IN THE UNITED STATES OR TO ANY "U.S. PERSONS" ("US PERSONS") AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933 (THE "SECURITIES ACT"). THIS FACTSHEET IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION, OR TO ANY OTHER PERSON, WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAW OR REGULATION.**

No part of this factsheet may be reproduced in any manner without the written permission of the Company. The possession or distribution of this factsheet in certain jurisdictions may be restricted by law and persons into whose possession this factsheet comes should inform themselves about and observe any applicable restrictions. This factsheet does not constitute or form a part of any offer to sell, or any solicitation of any offer to purchase or otherwise acquire, securities in any jurisdiction. The securities described in this factsheet may not be eligible for sale in certain jurisdictions or suitable for all types of investors. The Company has not been and will not be registered under the US Investment Company Act of 1940 (the "Investment Company Act") and the Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, transferred or delivered, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the

United States and in a manner which would not require the Company to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. This factsheet was prepared using the financial and other information available to the Company and Pharmakon Advisors LP as at the date of this factsheet. This information is believed to be accurate but has not been audited, reviewed or verified by any third party. This factsheet may describe past performance, which may not be indicative of future results. This factsheet may include statements regarding investment strategies, individual securities and economic and market conditions; however, there can be no guarantee that such statements will prove to be correct. This factsheet may include expressions of opinions that are speculative in nature and should not be relied on as statements of fact. This factsheet may include forward-looking statements which are subject to known and unknown risks and uncertainties that may cause actual results and events to differ materially from those expressed in or implied by such forward-looking statements. In some cases, forward-looking statements can be identified by words like "will seek", "will target", "believe", "expect", "intend", or similar expressions. You should not place undue reliance on forward-looking statements. Each of the Company and Pharmakon Advisors LP disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. Neither the Company nor Pharmakon Advisors LP accepts any liability for actions taken on the basis of the information provided in this factsheet. The information provided in this factsheet should not be considered a recommendation to buy, sell or hold any security.